Aqilion runs four innovative programs
The Aqilion team and network has extensive expertise and experience in inflammation. The company runs four innovative R&D programs. The Regulus program is the most advanced and Aqilion started a Phase 1 safety study in healthy volunteers in August 2022, to be followed by a Phase 2a study in eosinophilic esophagitis patients. EoE is an inflammatory disease of the esophagus and its main symptom is swallowing difficulties. The Girtab program is in preclinical stage and Alnitak and Polaris programs are in discovery phase.
All four in-house programs fit the collective experience of the Aqilion team and allow us to make optimal use of the expertise of our network and partners.